These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6418858)

  • 1. Dopamine receptor agonists: intrinsic activity vs. state of receptor.
    Carlsson A
    J Neural Transm; 1983; 57(4):309-15. PubMed ID: 6418858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist.
    Yasuda Y; Kikuchi T; Suzuki S; Tsutsui M; Yamada K; Hiyama T
    Life Sci; 1988; 42(20):1941-54. PubMed ID: 3130534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats.
    Arnt J; Hyttel J
    J Neural Transm; 1984; 60(3-4):205-23. PubMed ID: 6441835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intrinsic activities of the partial dopamine receptor agonists (-)-3-PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats.
    Carlsson M; Carlsson A; Eriksson E
    Eur J Pharmacol; 1987 Oct; 142(1):39-43. PubMed ID: 3691635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations.
    Clark D; Hjorth S; Carlsson A
    J Neural Transm; 1985; 62(3-4):171-207. PubMed ID: 2863323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological properties of presynaptic dopamine receptor agonists.
    Carlsson A
    Psychopharmacology Suppl; 1985; 2():31-8. PubMed ID: 3858802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of the enantiomers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) at dopamine receptor sites.
    Koch SW; Koe BK; Bacopoulos NG
    Eur J Pharmacol; 1983 Sep; 92(3-4):279-83. PubMed ID: 6138267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The intrinsic activity of (-)-3-PPP (preclamol) on pituitary DA receptors in female rats is enhanced following chronic DA depletion.
    Carlsson M; Eriksson E
    Life Sci; 1988; 42(5):585-8. PubMed ID: 3339950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioural stimulation is induced by separate dopamine D-1 and D-2 receptor sites in reserpine-pretreated but not in normal rats.
    Arnt J
    Eur J Pharmacol; 1985 Jul; 113(1):79-88. PubMed ID: 2931283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system.
    Hjorth S
    Acta Physiol Scand Suppl; 1983; 517():1-52. PubMed ID: 6138921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postsynaptic striatal dopamine agonist or antagonist actions of (+) or (-) 3-PPP and modification after receptor deafferentation.
    Oberlander C; Boissier JR
    J Pharmacol; 1983; 14(4):401-4. PubMed ID: 6423905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.
    Hjorth S; Carlsson A; Clark D; Svensson K; Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson LE; Johansson A
    Psychopharmacology (Berl); 1983; 81(2):89-99. PubMed ID: 6415751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the two partial D2 agonists (+)- and (-)-3-PPP on prolactin release in EEDQ treated male rats.
    Ekman A; Quiding M; Eriksson E
    Life Sci; 1991; 48(4):311-20. PubMed ID: 1671291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the enantiomers of 3-PPP on DA1 and DA2 dopamine receptors in the dog.
    Kohli JD; Glock D; Goldberg LI
    Eur J Pharmacol; 1985 Aug; 114(3):305-10. PubMed ID: 4065203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for heterogeneous rotational responsiveness to apomorphine, 3-PPP and SKF 38393 in 6-hydroxydopamine-denervated rats.
    Fenton HM; Leszczak E; Gerhardt S; Liebman JM
    Eur J Pharmacol; 1984 Nov; 106(2):363-72. PubMed ID: 6442233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.
    Clark D; Hjorth S; Carlsson A
    J Neural Transm; 1985; 62(1-2):1-52. PubMed ID: 3894582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine receptor-mediated hypothermia induced in rats by (+)-, but not by (-)-3-PPP.
    Hjorth S; Carlsson A; Clark D; Svensson K; Sanchez D
    Eur J Pharmacol; 1985 Jan; 107(3):299-304. PubMed ID: 3979430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The partial dopamine receptor agonists (--)-3-PPP and transdihydrolisuride enhance prolactin secretion in female but not in male rats.
    Carlsson M; Eriksson E
    J Neural Transm; 1989; 77(2-3):211-6. PubMed ID: 2569498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous rotational responsiveness in 6-hydroxydopamine-denervated rats: pharmacological and neurochemical characterization.
    Liebman JM; Gerber R; Hall NR; Altar CA
    Psychopharmacology (Berl); 1988; 96(4):477-83. PubMed ID: 3149769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.